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Abstract
Autism is a highly heritable neurodevelopmental disorder, yet the genetic underpinnings of the disorder are largely
unknown. Aberrant brain overgrowth is a well-replicated observation in the autism literature; but association, linkage, and
expression studies have not identified genetic factors that explain this trajectory. Few studies have had sufficient statistical
power to investigate whole-genome gene expression and genotypic variation in the autistic brain, especially in regions that
display the greatest growth abnormality. Previous functional genomic studies have identified possible alterations in
transcript levels of genes related to neurodevelopment and immune function. Thus, there is a need for genetic studies
involving key brain regions to replicate these findings and solidify the role of particular functional pathways in autism
pathogenesis. We therefore sought to identify abnormal brain gene expression patterns via whole-genome analysis of
mRNA levels and copy number variations (CNVs) in autistic and control postmortem brain samples. We focused on
prefrontal cortex tissue where excess neuron numbers and cortical overgrowth are pronounced in the majority of autism
cases. We found evidence for dysregulation in pathways governing cell number, cortical patterning, and differentiation in
young autistic prefrontal cortex. In contrast, adult autistic prefrontal cortex showed dysregulation of signaling and repair
pathways. Genes regulating cell cycle also exhibited autism-specific CNVs in DNA derived from prefrontal cortex, and these
genes were significantly associated with autism in genome-wide association study datasets. Our results suggest that CNVs
and age-dependent gene expression changes in autism may reflect distinct pathological processes in the developing versus
the mature autistic prefrontal cortex. Our results raise the hypothesis that genetic dysregulation in the developing brain
leads to abnormal regional patterning, excess prefrontal neurons, cortical overgrowth, and neural dysfunction in autism.
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Introduction
Clinical and subclinical manifestations of autism begin during
the first years of life [1]. Neuroimaging studies of living infants and
young children with autism have revealed abnormal brain
overgrowth in the majority of cases, particularly in prefrontal,
temporal and amygdala regions [2–13]. These studies have also
shown abnormal functional asymmetry and activation in the
cortex and cerebellum [14–16]. Children with autism have 67%
excess neuron numbers in the prefrontal cortex, a substantial
pathology that points to disruption of early developmental
mechanisms that govern neuron numbers, and an 18% increase
in brain weight at autopsy [17]. However, by late adolescence and
early adulthood, the autistic brain commonly displays neuron
loss and cortical thinning and is no longer enlarged [2,8,13,18].
Therefore, the underlying developmental molecular defects in the
majority of autistic cases seem likely to be most evident at younger
rather than older ages.
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postmortem analyses of the autistic brain is 22 years [19], making
it difficult if not impossible to comprehensively assess early
developmental molecular pathologies associated with autism. In
studies combining both young and adult autistic brain tissue,
transcript and protein expression patterns suggest that cortical
patterning, synaptic [20], apoptotic [21], immune [20,22], and
inflammatory [23] aberrances in addition to dysregulation of
neurotransmitter systems [24] may be involved in autism. None of
these molecular pathologies at older ages, however, can explain
the 67% excess prefrontal neuron numbers and brain enlargement
at younger ages in autism.
Thus, there seems to be a gap between neuroanatomical and
cellular abnormalities reported for autism at younger ages and
molecular pathologies in autism at older ages. Molecular
pathologies specifically present at younger ages in autism are
largely unknown and unexplored. Also, whether some molecular
abnormalities detected in the older autistic brain reflect conditions
unique to the older brain and whether others are common to both
younger and older autistic brains are unknown. Genome-wide
analyses of the genes, pathways and processes that exhibit
dysregulation specifically in the young autistic brain have not
been pursued to a great degree. This is particularly true for the
prefrontal and temporal cortex, where abnormalities of growth
and function during early development are pronounced and likely
to contribute significantly to social, communication, language and
emotional deficits associated with autism. Additionally, although
copy number variation (CNV) has been hypothesized to play an
important role in the pathogenesis of autism [25,26] and may
underlie important differences in gene expression, CNVs identified
in brain tissue from individuals with autism have not been
examined in relation to aberrant brain gene expression from the
same tissue samples.
We examined the linked hypotheses that underlying neuroan-
atomical differences between younger and adult individuals with
autism are a result of differences in molecular pathology. We
hypothesize that some molecular pathologies at younger ages in
autism may provide insight into the very early neural develop-
mental processes that lead to the disorder. To do so, we identified
abnormal genetic pathways in the young autistic brain, deter-
mined expression patterns that distinguished the young from the
adult autistic brain and identified evidence for gene expression
dysregulation that is age-independent using genome-wide expres-
sion and genotyping techniques. We found age-dependent gene
expression differences between young and adult autistic brains as
well as rare and common genetic variants associated with autism
that have important roles in neurodevelopment.
Results
First, we analyzed genome-wide expression of 57 frozen samples
of dorsolateral prefrontal cortex (DLPFC, BA 9/46; Table S1)
using a DASL-based platform on the Illumina Human-Ref8 v3
microarray [27,28]. Thirty-three samples in total passed quality
control measures (Text S1): 16 of these samples were from young
postmortem males (2–14 y; autism=9, control=7) and 17 were
from adult males (15–56 y, autism=6, control=11). Though
RNA Integrity Numbers (RIN) are not predictive of array quality
[29], multiple RIN assessments were used to determine RNA
quality (Table S1). We found no significant differences between
the RINs of the autism and control groups (t=0.16, DF=20,
p=0.87).
Two-way analysis of variance (ANOVA) and post-hoc pair-wise
ANOVA-based comparisons were performed to identify genes
exhibiting expression differences in young autistic vs. young
control DLPFC compared to adult autistic vs. adult control
DLPFC. An overall ANOVA-based F-test p-value,0.05 [empir-
ical false discovery rate (FDR), not threshold, FDR=0.27] was
used to identify genes showing an effect of interaction between age
and diagnosis for further analyses. From the two-way ANOVA
results, we attempted to tease out expression differences between:
1) young autism, 2) young control, 3) adult autism and 4) adult
control groups.
Of the genes exhibiting an effect of interaction from ANOVA-
based F-tests with p-values,0.05, 102 genes resulted in ANOVA-
based post-hoc contrasts between young autistic and control
groups with p-value,0.05 (Figure S1). Seven hundred thirty six
genes resulted in an ANOVA-based post-hoc contrast between
adult autistic and control cases (p-value,0.05). Finally, an overall
ANOVA-based F-test p-value,0.05 (empirical FDR=0.13) was
performed to assess the main effect of diagnosis across all autistic
and control cases independent of age. Two thousand seventeen
genes resulted in this contrast with p-value,0.05. Genes common
between the three comparisons are shown in Figure S1.
Genes exhibiting a diagnosis main effect and a post-hoc pairwise
contrast (e.g., autism vs. control, adult vs. young; p-value,0.05)
were further subjected to enrichment analyses in the MetaCore
software suite (MetaCore from GeneGo Inc.) as well as the online
enrichment program DAVID [30,31]. By focusing on genes
exhibiting a diagnosis main effect, we explored pathological
mRNA expression in autism irrespective of age. qPCR validation
verified expression differences on a subset of the differentially
expressed genes (Figure S2).
Genes regulating cell number, genetic integrity, and
neural patterning are dysregulated in young autistic
cases
Since early brain overgrowth and the clinical onset of autistic
symptoms occur at young ages in autism, we focused on unique
gene expression differences between autistic and control cases
below the age of 14 years to identify genes that may be
dysregulated early in autism pathogenesis. One hundred two
genes were differentially expressed in young autistic cases
compared with the young control group and exhibited a diagnosis
x age group interaction effect (p-value,0.05, empirical
Author Summary
Autism is a disorder characterized by aberrant social,
communication, and restricted and repetitive behaviors. It
develops clinically in the first years of life. Toddlers and
children with autism often exhibit early brain enlargement
and excess neuron numbers in the prefrontal cortex.
Adults with autism generally do not display enlargement
but instead may have a smaller brain size. Thus, we
investigated DNA and mRNA patterns in prefrontal cortex
from young versus adult postmortem individuals with
autism to identify age-related gene expression differences
as well as possible genetic correlates of abnormal brain
enlargement, excess neuron numbers, and abnormal
functioning in this disorder. We found abnormalities in
genetic pathways governing cell number, neurodevelop-
ment, and cortical lateralization in autism. We also found
that the key pathways associated with autism are different
between younger and older autistic individuals. These
findings suggest that dysregulated gene pathways in the
early stages of neurodevelopment could lead to later
behavioral and cognitive deficits associated with autism.
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identified autism candidate loci based on the literature (Table S3).
Pathway enrichment analyses of these 102 genes via the
MetaCore software suite (defining an enriched pathway as having
an enrichment p-value,0.05 and empirical FDR,0.1) suggested
that DNA damage-response, cell cycle and apoptosis-related
MetaCore pathways (‘M-Pathways’) were significantly altered
(Table 1, Young autism versus young control map folders). Key
players such as BRCA1 and CHK2 were downregulated. Most
significantly dysregulated M-Pathways in this category included
the DNA-damage-induced response and role of NFBD1 in DNA
damage response. A Development-Neurogenesis Process Network,
Development-Neurogenesis (p=1.09E-03, 6/192 network ob-
jects), was also significantly altered.
We additionally annotated all 102 genes using DAVID and
identified overlapping sets of 12, 19, 7 and 16 genes involved in
DNA damage/cell cycle, apoptosis, immune signaling and
neurogenesis and neural development (Figure 1), respectively. Of
the 7 immune response genes, 4 (FAS, BCL3, GREM1 and
FOSL2) were also found to contribute to apoptosis. Neurogenesis
and neural development pathways included the WNT pathway
and were driven by dysregulation of the WNT3 gene. WNT
pathway genes are known to regulate cell proliferation, cell fate
and patterning during embryogenesis [32]. Downstream compo-
nents of the WNT pathway, such as Dvl1, are also known to
regulate social behavior in mouse models [33]. In addition, we
found significant downregulation of genes involved in neural
patterning and differentiation, such as FGF1, HOXD1, NDE1,
NODAL, PCSK6 and GREM1 (Figure 1, Table S2).
Expression anomalies of genes involved in DNA damage, cell
cycle and apoptosis may contribute to abnormal brain growth by
increasing production or reducing elimination of neurons during
development. Dysregulated neural patterning and differentiation
genes may lead to abnormal cellular organization and cytoarchi-
tecture. For example, HOX and DLX family genes play important
roles in vertebrate patterning and are important for neuronal
subtype differentiation [34]. Moreover, NODAL controls dorsal
mesoderm induction, anterior patterning and initiation of left-right
asymmetry during gastrulation [35]. These findings suggest that in
the young autistic brain, genetic regulation of cell number, genetic
integrity and neural patterning is disturbed.
Genes regulating signaling, repair, and response
pathways are dysregulated in adult autistic cases
As a complement to the analyses of the young autistic brain, we
compared the genes dysregulated in young autistic cases to those
dysregulated in adult autistic cases. We identified genes using the
same ANOVA diagnosis x age interaction effect p-value criterion
but with emphasis on genes differentially expressed in adult autistic
brains relative to adult control brains (defined as cases $15 years
of age). Seven hundred thirty six genes were differentially
expressed based on this analysis (Figure S1, Table S4). These
genes were also analyzed with MetaCore for functional enrich-
ment. The 3 most significant MetaCore Map Folders (‘Map
Folders’: a label MetaCore provides to sets of genes with an
overarching function of pathway participation) included cell
differentiation, mitogenic signaling and apoptosis genes (Table 1,
Adult autism versus adult control map folders, Figure 2A; p,0.05,
FDR,0.1). Dysregulated pathways specific for the adult brain
included multiple signaling and remodeling functions in neurons
and glia (Table 1, Adult autism versus adult control map folders).
M-Pathway categories that were dysregulated in adults but not
young cases included development, signaling and oxidative stress
pathways (Table 1, Figure 2B).
The Cell Differentiation Map Folder included significantly
dysregulated genes RELN, BTRC, BMP4, MAPK10 and NTRK3
(Figure 2A). This Map Folder also included suggested dysregula-
tion of the ‘Activin A in Cell Differentiation and Proliferation’
pathway, which involved the genes LHB, NODAL, STAR,
CDKN1A, PRKAR1A and ADCY6. Genes playing multiple
functions in all three top map folders included MAPK12,
CDKN1A, NTRK3, PRKAR1A, PIK3CA, CASP9, MAPK10,
ADCY6 and MAGED1 (Figure 2A). Notably, Tissue Remodeling
and Wound Repair-related genes also exhibited dysregulation in
adult autistic cases (Table 1, Adult autism versus adult control map
folders).
These analyses suggest that in the adult autistic brain, cell
differentiation, mitogenic, apoptotic and remodeling and repair
functions could be components of recovery responses, in
accordance with previous reports [22,23,36]. They could,
however, also be signatures of ongoing reparatory neurogenesis
processes [37]. For example, the Activin A signaling pathway is
expressed by neurons following injury and is essential for adult
neurogenesis [38,39]. BTRC inhibits the beta-catenin (CTNNB1)
pathway [40], which in adult animals is upregulated after insults
such as seizures [41] and promotes adult neurogenesis [42].
Furthermore, BMP4 expressed in adult subventricular zones serves
to inhibit neurogenesis [43]. Thus, it appears that aberrant
signaling and repair processes may distinguish adult autistic cases
from young cases.
Genes important in development were dysregulated
across both young and adult autistic cases
Finally, we examined genes showing a main effect of diagnosis
to identify differentially expressed between autistic and control
cases independent of age (i.e., we did not confine attention to genes
exhibiting diagnosis x age interaction effects or age-specific effects).
More than 2000 such genes were detected based on a simple
contrast between autism and control brains (p,0.05, empirical
FDR=0.13; Figure S1, Table S5). Enrichment analyses of these
genes using MetaCore suggested that seventeen Map Folders were
altered in all autistic brains (p,0.05, FDR=0.1; Table 1,
Diagnosis main effect map folders). The three most significant
Map Folders included DNA-damage response, apoptosis and
immune system response functions (Figure 3, Figure S3). In
addition, the top 25 M-Pathways (Table 1, Diagnosis main effect
map folders, Table S6) included cell cycle [14-3-3 (YWHAZ),
CDC25A, CDCD25C, ATRX], proliferation [CTNNB1 (beta-
catenin), FSHB, PRKACB, PRKCZ], apoptosis (BAD, CASP8,
CASP10, MDM2), cytoskeleton and extracellular matrix remod-
eling (ErbB4, MMP2, NID1, TIMP1, COL4A3) and growth and
development [RELN, ROBO1, ADORA2A, p21 (CDKN1A), 14-
3-3, HGF, FGFRL1, TSC1] functions. Specifically, the p53
signaling pathway and the PTEN pathway were among these
dysregulated M-Pathways (Table 1, Diagnosis main effect map
folders).
A number of genes in these M-Pathways have known functions
in neuronal development: PTEN signaling regulates proliferation
[44] and is associated with macrocephaly in autism [45,46]. TSC1
is mutated in tuberous sclerosis, acts downstream of PTEN in the
mTOR pathway [47] and affects cortical lamination, neuronal
migration and axon pathfinding [48]. CTNNB1, a key member of
the WNT pathway, regulates cerebral cortical size. CTNNB1
transgenic mice have enlarged and folded cortices [49]. Further-
more, RELN is critical for human neuronal migration [50] and
has been previously linked to autism [51]. Genes differentiating
autistic cases from controls independent of age have important
developmental, immune and cytoskeletal remodeling functions.
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Young autism versus young
control map folders P-value Ratio Young autism vs. young control pathway name P-value
Network
objects
No significant map folders DNA damage_DNA-damage-induced responses 0.0004634 2/9
Immune response_NF-AT signaling and leukocyte interactions 0.0006138 3/46
DNA damage_Role of NFBD1 in DNA damage response 0.000995 2/13
Apoptosis and survival_DNA-damage-induced apoptosis 0.001333 2/15
DNA damage_ATM/ATR regulation of G2/M checkpoint 0.004024 2/26
DNA damage_Brca1 as a transcription regulator 0.005337 2/30
DNA damage_Role of Brca1 and Brca2 in DNA repair 0.005337 2/30
DNA damage_ATM/ATR regulation of G1/S checkpoint 0.006058 2/32
Cell cycle_Regulation of G1/S transition (part 1) 0.008469 2/38
Translation _Regulation of EIF2 activity 0.008907 2/39
Adult autism versus adult
control map folders P-value Ratio Adult autism vs. adult control pathway name P-value
Network
objects
Cell differentiation 0.000008641 37/920 Development_Role of Activin A in cell differentiation
and proliferation
0.00006435 6/40
Mitogenic signaling 0.0001335 24/548 Signal transduction_PKA signaling 0.0002574 6/51
Apoptosis 0.0001475 31/809 Development_MAG-dependent inhibition of neurite outgrowth 0.0004451 5/37
Tissue remodeling and wound repair 0.0007248 21/504 Cell cycle_Regulation of G1/S transition (part 1) 0.0005053 5/38
Cystic fibrosis disease 0.00727 22/649 Development_A2A receptor signaling 0.0009027 5/43
Vasoconstriction 0.007939 13/312 Neurophysiological process_PGE2-induced pain processing 0.0009027 5/43
DNA-damage response 0.008795 13/316 ENaC regulation in airways (normal and CF) 0.002146 5/52
Immune system response 0.009623 28/914 Apoptosis and survival_Endoplasmic reticulum
stress response pathway
0.002336 5/53
Vasodilation 0.009723 13/320 Development_Activation of astroglial cells proliferation by ACM3 0.002572 4/33
Neurotransmission 0.01026 22/669 Signal transduction_Activin A signaling regulation 0.002572 4/33
Vascular development (Angiogenesis) 0.01195 17/479 Oxidative stress_Role of ASK1 under oxidative stress 0.002876 4/34
Cardiac Hypertrophy 0.01211 9/190 Apoptosis and survival_Role of CDK5 in
neuronal death and survival
0.002876 4/34
Protein degradation 0.01665 11/270 Fatty Acid Omega Oxidation 0.002876 4/34
Estrogen signaling 0.02384 11/285 Development_Role of CDK5 in neuronal development 0.002876 4/34
Inflammatory response 0.03608 18/585
Protein synthesis 0.03667 11/305
Calcium signaling 0.03896 14/426
Blood clotting 0.04603 10/278
Diagnosis main effect map folders P-value Ratio Diagnosis main effect pathway name P-value
Network
objects
DNA-damage response 2.98E-07 32/316 Development_A2A receptor signaling 1.704E-07 11/43
Apoptosis 8.41E-07 58/809 Development_A2B receptor: action via G-protein alpha s 0.000007049 10/50
Immune system response 4.62E-06 61/914 Transcription_P53 signaling pathway 0.00004903 8/39
Tissue remodeling and wound repair 5.48E-06 40/504 Transcription_CREB pathway 0.0001213 8/44
Cell differentiation 5.73E-06 61/920 Development_Thrombopoietin-regulated cell processes 0.0001431 8/45
Vascular development (Angiogenesis) 2.38E-05 37/479 Development_PIP3 signaling in cardiac myocytes 0.0001965 8/47
Cardiac Hypertrophy 3.28E-05 20/190 Cell adhesion_ECM remodeling 0.000404 8/52
Inflammatory response 3.69E-05 42/585 Cell cycle_Role of 14-3-3 proteins in cell cycle regulation 0.00082 5/22
Cell cycle and its regulation 8.89E-05 32/414 Cytoskeleton remodeling_Cytoskeleton remodeling 0.000841 11/102
Mitogenic signaling 1.90E-04 38/548 Reproduction_GnRH signaling 0.0008578 9/72
Vasodilation 1.93E-04 26/320 Development_Role of IL-8 in angiogenesis 0.000858 8/58
Hematopoiesis 2.07E-04 23/268 Immune response_MIF - the neuroendocrine-macrophage connector 0.0009946 7/46
Calcium signaling 3.43E-04 31/426 Signal transduction_PTEN pathway 0.0009946 7/46
Vasoconstriction 3.77E-03 22/312 Development_HGF signaling pathway 0.001134 7/47
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Pathways identified in this analysis, we revisited the 102 significant
genes identified in the young autism vs. control analysis. We found
17 cytoskeletal and matrix remodeling genes (Figure 1). These
analyses support a role for cytoskeletal dysregulation in young
autistic brains as well. Cytoskeletal elements have been linked to
defects in neuronal migration in other neurodevelopmental
disorders such as lissencephaly [52].
Comparison with a published functional genomic study
shows overlap in repair and immune response genes
Due to commonalities between previously identified candidate
loci and the genes we found to exhibit expression differences
between young autism vs. control, we also investigated similarities
between the genes we identified and those identified in a recent
functional genomic study. We compared genes showing a main
effect of diagnosis in the present study with differentially expressed
genes implicated recently by Voineagu et al. [20].
Twenty-five probes detected as p,0.05 in comparing autism
and control cases and 21,564 probes detected as p.0.05 in both
studies were identified as overlapping (p,0.0001). Among the
probes detected at p,0.05 were 6 genes important for Tissue
Remodeling and Wound Repair (p=1.622E-4, FDR,0.05) and 7
genes important for Immune System Response (p=4.772E-4,
FDR,0.05). Ultimately, we found some consistency between
genes detected in our analyses with those of a previous functional
genomic study, particularly within domains of repair and immune
response.
Genetic variation may underlie cell cycle and
cytoskeleton gene dysregulation
To further investigate the findings of dysregulated genetic
functions in young autistic cases particularly, we determined
whether CNVs in autistic cases were distinct from those in controls.
We genotyped prefrontal cortex samples from 55 of the 57 total
autistic and control cases in our study. After quality control, CNV
enrichment was analyzed in 30 DLPFC cases from male and female
autistic and control cases (Table S1) using PennCNV with GC
adjustment and CNVision programs [53,54]. Nearly all (.99%)
brain-derived CNVs in autistic and control cases were deletions
(Table S7, Table S8). There were no differences between autistic
and control cases in numbers of CNVs, numbers of genes per CNV
or average CNV size (Figure S4).
Restricting analysis to male cases, genes identified in the autistic
group were enriched in cell cycle (mitosis and S phase, including
BUBR1, Cyclin B, BRCA1, RAD51, CRM1, RFC2 and LIS1)
and cytoskeleton (spindle and cytoplasmic microtubules, including
CLIP170, Tubulin alpha, Dynein light and heavy chains, DNAL1
and ROD) GeneGO Process Networks. No significant enrichment
was identified in the gene content of controls (Figure 4). Similar
network enrichment was noted in male autistic cases after filtering
out common, non-pathogenic CNVs (Materials and Methods),
while no significant network enrichment was found in controls
(Figure 4). Notably, BRCA1 expression was found to be
dysregulated in the young autistic brain (Figure 1) and predicted
as deleted in the CNV analysis (Table S7). Subsequent enrichment
analysis of CNVs present in male and female autistic and control
cases yielded similar results (Figure S4). These results are
consistent with the above described gene expression results
showing abnormal expression of cell cycle and developmental
pathways in the autistic cases.
To extend these genotypic findings and specifically test whether
common variants of cell cycle genes are associated with autism, we
determined whether common variants in processes involved in cell
cycle and other hypothesized regulatory processes were associated
with autism using two previously analyzed SNP datasets: one from
the Autism Genetic Resource Exchange (AGRE) and National
Institutes of Mental Health genotyped at the Broad Institute and
Johns Hopkins Medical Institute (Broad/JHMI) and another from
AGRE genotyped at the Children’s Hospital of Philadelphia
(CHOP) [55,56]. Set-based association analysis was applied to the
Broad/JHMI dataset (Materials and Methods). Four sets of genes
postulated to be involved in brain overgrowth (cell cycle, WNT
pathway, growth factors and apoptosis) were used as experimental
sets for analysis, while other postulated pathological processes such
as synaptogenesis and inflammation were used as controls.
We found nominal associations of only cell cycle-related genes
with ASD (Figure 4, p=0.037). Cell cycle genes were then
subdivided into twenty-one subgroups. Genes regulating cell cycle
senescence (p=0.011), the G2-M phase transition (p=0.028) and
Table 1. Cont.
Diagnosis main effect map folders P-value Ratio Diagnosis main effect pathway name P-value
Network
objects
Myogenesis regulation 3.48E-02 8/99 Development_A3 receptor signaling 0.00146 7/49
Blood clotting 3.64E-02 17/278 Development_GM-CSF signaling 0.001647 7/50
Protein synthesis 4.29E-02 18/305 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 0.001692 11/111
Development_IGF-1 receptor signaling 0.001853 7/51
Signal transduction_cAMP signaling 0.001878 6/38
Cell adhesion_PLAU signaling 0.002156 6/39
DNA damage_Role of SUMO in p53 regulation 0.002442 4/17
Cell adhesion_Chemokines and adhesion 0.00254 10/100
Proteolysis_Putative SUMO-1 pathway 0.003026 5/29
Apoptosis and survival_BAD phosphorylation 0.003175 6/42
Development_Osteopontin signaling in osteoclasts 0.003529 5/30
(A–C) MetaCore Map Folders and M-Pathways identified in posthoc young autism vs. young control analysis (p,0.05, FDR=0.1; A), posthoc adult autism vs. adult
control analysis (p,0.05, FDR=0.1; B) and diagnosis main effect analyses comparing all autism and all control cases (Top 25; C). P-values and numbers of network
objects/ratios of differentially expressed genes are shown.
doi:10.1371/journal.pgen.1002592.t001
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PLoS Genetics | www.plosgenetics.org 5 March 2012 | Volume 8 | Issue 3 | e1002592Figure 1. Dysregulated gene expression in developmental M-Pathways and Process Networks in young autistic prefrontal cortex.
From differentially expressed genes of young autistic vs. young control cases (Table S2), networks were created using MetaCore Network Analysis.
Colors on fold change graph correspond to circles on the right depicting network maps in each category. Yellow=differentially expressed genes in
two or more functional domains. Overlapping circles=differentially expressed genes common to two domains.
doi:10.1371/journal.pgen.1002592.g001
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associated with autism in the Broad/JHMI dataset (Figure 4).
Because these analyses were not statistically corrected for the
number of pathways considered, the findings were replicated for
the three significant subcategories (p,0.05) of cell cycle genes
using the independent CHOP dataset (Figure 4). Two of the
subcategories (senescence and G0-G1 phase transition) were
replicated (p,0.0328 and p,0.0093 respectively), while the third
(G2-M phase transition) was not. These results suggest that
abnormal expression of cell cycle and developmental pathways
may originate from genetic variation.
Discussion
Using genome-wide expression and CNV detection techniques,
we discovered specific developmental pathways and processes in
the prefrontal cortex that are significantly abnormal in younger
autistic cases, other non-developmental processes that are
dysregulated in older autism cases and, finally, processes common
across younger and older ages in autism. Age-dependent gene
expression alterations may underlie the differences in cellular and
neuroanatomical pathologies between young and adult ages in
autism that have been previously reported in MRI and
postmortem research [13,19]. In addition, we uncovered possible
genotypic sources of developmental abnormalities in autism.
The young autistic prefrontal cortex displays
dysregulated developmental genes
It is widely held that maldevelopment of the prefrontal cortex,
in conjunction with several other cortical and subcortical regions,
plays a pivotal role in the social, communication, cognitive and
Figure 2. Dysregulated gene expression in top three Map Folders in adult autistic prefrontal cortex and differentially affected M-
Pathways of young and adult autistic cases. (A) Graph on the right shows fold change of genes in cell differentiation, mitogenic signaling, and
apoptosis and survival Map Folders. Colors on fold change graph correspond to circles on the left depicting network maps in each category. From
each category of differentially expressed genes in adult autistic vs. adult control posthoc comparison (Table S4), gene networks on the left were
created using MetaCore Network Analysis. (B) Top differentially affected M-pathway comparisons of dysregulated genes between adult and young
autistic cases. Bars represent significance of listed pathways. Orange=adult; blue=young; faded color=FDR.0.1 or p.0.05.
doi:10.1371/journal.pgen.1002592.g002
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young autistic prefrontal cortex displayed disturbances in critical
developmental pathways and processes that govern cell number,
cortical patterning and differentiation, including those regulating
proliferation, cell cycle, DNA damage response and apoptosis and
survival. We hypothesize that such dysregulation could be the basis
of the 67% excess neuron numbers also reported for prefrontal
cortex in children with autism [17]. The top dysregulated pathway
map in the young autistic brain was the A2A receptor signaling
pathway (Table 1, Diagnosis main effect map folders). Adenosine
receptors play important roles for both brain development and
function including the regulation of neuronal stem cell prolifer-
ation (via nitric oxide signaling) [57], synaptic plasticity, motor
function, cognition and emotion-related behaviors. This pathway
has been a therapeutic target for studies of other complex
neurologic and psychiatric disorders [58].
Figure 3. Dysregulated gene expression in top two MetaCore Map Folders in autism independent of age. Graph on left shows fold
change of genes in DNA damage response and apoptosis and survival Map Folders. The third most significant map folder is depicted in Figure S3.
Colors on fold change graph correspond to circles on the left depicting network maps in each category. From each category of differentially
expressed genes in the all autistic vs. all control comparison (Table S5), networks were created using MetaCore Network Analysis.
doi:10.1371/journal.pgen.1002592.g003
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patterning pathways that regulate normal anterior/posterior and
dorsal/ventral patterning as well as right/left asymmetry. At
young ages in autism, MRI evidence indicates disruption of
normal cortical patterning with gray matter enlargement greatest
in anterior dorsolateral prefrontal cortex and least in posterior
occipital and ventral orbital prefrontal cortex [3,6,19]. It will be
important to further investigate the possible role that genetic
dysregulation of neural patterning may play in causing abnormal
left/right functional and structural asymmetries in addition to
abnormal anterior/posterior and dorsal/ventral gradients that
have been reported in autistic infants, children and adults
[3,6,14,15,19,59]. Dysregulation of proliferation, cell cycle and
apoptosis may be involved in early brain overgrowth in autism and
excess neuron numbers in the prefrontal cortex [17] and could
therefore contribute to dysfunction at the neural systems level
[19,26,60,61]
The adult autism prefrontal cortex displays arrested
growth and degeneration
In contrast to the younger autistic brain [62], the adult autistic
brain shows evidence of neuron loss, reduced or arrested growth,
cortical thinning and possible degeneration. It has been speculated
that such pathologies may be related directly or indirectly to the
earlier pathological overgrowth. It is known that the functions of
genes are modulated by the age of the organism, such that
Figure 4. MetaCore process networks and network maps in autism based on gene deletions located in CNVs from DLPFC, and
genetic association results. Autistic cases had significant enrichment of MetaCore process networks in genes contained within total CNVs (A) and
filtered CNVs (i.e., not present in the Database of Genomic Variants) using PennCNV (B) and CNVision (C). Blue bars=controls; red bars=autistic cases.
(D) MetaCore network analysis of the top three enriched MetaCore process networks in (B). Symbols in (D) represent gene types or associations.
Genes with blue circles were identified autistic CNVs; genes without circles were summoned by the database to complete network. Pink
lines=canonical pathway connections. (E) Gene sets tested in set-based association analysis using PLINK in Broad/JHMI and CHOP datasets, number
of genes in each set, database from which genes were taken and p-values of associations.
doi:10.1371/journal.pgen.1002592.g004
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cases may have differing consequences. Genes such as BMP4 and
BTRC, which have important functions in neurodevelopment, may
regulate recovery functions such as neurogenesis in the adult brain
[63–65]. Furthermore, we found that genes involved in cell
differentiation, including RELN, BMP4, NODAL and NTRK3,
and tissue remodeling and wound repair are dysregulated in adults.
Though the literature on adult neurogenesis and cell differentiation
is sparse, recent studies propose that the brain activates these
mechanisms in response to injury in the neocortex [66,67]. In the
context of brain overgrowth, these data suggest the hypothesis that
reactive reorganization of functional genetic networks and processes
may occur in the adult autistic brain. Such functional reorganiza-
tion of genetic modules or networks has recently been described for
systems that regulate DNA-damage responses [68].
Age-independent differential expression represents
pathological developmental processes
To complement analyses of age-specific expression pathology in
autism, we also identified gene expression abnormalities in autism
that were age independent. Among the most abnormally expressed
genes were those that regulate DNA-damage response, apoptosis
and immune system response functions. These genetic systems
play important roles during development of the central nervous
system [69–71] and suggest that the brain in autism arises from
defects during this critical period. Several lines of evidence indicate
that immune system responses closely participate in the neuro-
pathogenesis of ASD both at young and adult ages. Although little
is known about this role, both inflammatory and autoimmune
mechanisms are necessary for normal neurodevelopment and are
found to be altered in ASD [72]. Microglia activation and
increases in inflammatory cytokine and chemokine production
have direct effects on neuronal development by affecting cellular
proliferation, migration and differentiation as well as synapse
formation [72]. For example, TNF-a can modulate neuronal cell
proliferation or cell death and plays an important role in synaptic
pruning [73,74]. In addition, auto-antibodies may affect receptor
function, activate neuronal and glial cells and induce cellular
damage or death [72].
More work remains to be done, however, to uncover the
significance of these pathways in the postnatal brain. These results
may point to mechanisms in the brain that are continuously
pathological throughout the lifespan in autism and suggest possible
candidates for genetic therapies.
Genes in common with a previous genetic study support
pathway results
While large sample in vivo studies, such as Pinto et al. [26], have
identified potential functional genomic abnormalities in autism,
biological validation requires postmortem studies, such as the
present one and Voineagu et al. [20]. The comparison of findings
between the present study and Voineagu et al. [20] demonstrates a
consistent overlap involving several pathways including repair-
and immune-related processes.
We speculate that the aberrances in these genes, which may be
distinct from individual to individual, may collectively underlie the
repair or response mechanisms in the mature autistic brain.
Commonalities across autistic brains may converge at the level of
disturbances in these genetic pathways, and monitoring most
commonly affected pathways across functional genomic studies
may help subgroup different pathogenic mechanisms.
Though these genetic pathways with high impact on autism
susceptibility may be similar between studies, there are also
copious pathways that are disparate. The differences in the results
between our study and Voineagu et al. [20] may be due to genetic
heterogeneity, different criteria for sample selection and age and
gender distribution. For example, although our studies assayed a
similar number of postmortem cases, our sample consisted of all
male autistic and control cases, while that of Voineagu et al. [20]
consisted of 36% female autistic and 6% female control cases.
Also, to identify gene expression abnormalities in the young
autistic brain, we compared expression in the young autistic brain
to the young control brain, while Voineagu et al. [20] lacked
young controls. Thus, some effects that we observed may not have
been identified in Voineagu et al. [20] because of differences in
study design.
Copy number anomalies in autism
Our analyses using mRNA and DNA from the same cortices
suggest that a large and heterogeneous array of genes and gene
expression abnormalities regulate multiple foundational prenatal
processes critical to cortex formation. Although DNA defects vary
from autistic case to case, the diverse genetic deletions seem to
underlie a relatively common biological theme, hitting a shared set
of gene pathways that impact cell cycle, DNA damage detection
and repair, migration, neural patterning and cell differentiation.
The set of functional gene pathways identified by our direct
analyses of autistic brain tissue are consistent with those identified
by CNV pathway enrichment analyses in living autistic patients
[26].
Conclusion
In this study, we found evidence for distinct gene expression
anomalies in the prefrontal cortex of young autistic individuals
that may underlie structural and functional maldevelopment of
this and other association cortices. Our evidence shows that some
important gene expression abnormalities in the prefrontal cortex
change with age in autism and such changes may be related to
findings in other studies that report a shift in morphology and
function in the adult autistic brain. Enrichment of CNVs and
association analysis of cell cycle gene sets, in accordance with early
expression defects of cell cycle mechanisms, suggest that genetic
variation may contribute to this dysregulation. We also found that
irrespective of age, the expression of atypical developmental
processes distinguish the autistic brain from that of control
individuals. The modulation of these expression mechanisms may
underlie the abnormal brain growth trajectory in autism. Further
knowledge of the specific developmental neurobiological mecha-
nisms behind the age-dependent anomalies reported here could
point to distinct early developmental processes that lead to autism,
uncover mechanisms that respond to early pathologies in the
mature brain and suggest novel molecular targets for prevention
strategies and treatment over the course of the disorder.
Materials and Methods
Gene expression analysis
Ethics statement. All cases are deceased and are deidentified
by the brain banks where tissue was obtained. However, the same
human protections procedures were employed as for live subjects.
Research procedures employed in this study were approved by the
institutional review board of the University of California, San
Diego (protocol number 091205).
RNA extraction and quantification. A full description of
the methods is provided in Text S1. Extraction of total RNA from
5–10 mg of frozen brain tissue from grey and white matter of
prefrontal cortex of 57 postmortem autism and control cases aged
Autism Gene Expression and Copy Number Anomalies
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to manufacturer’s instructions. Select samples were analyzed using
Bioanalyzer (Agilent) according to the manufacturer’s protocol for
quality control and quantification (Table S1). RNA from
remaining samples was quantified using a NanoDrop
spectrophotometer.
Microarray processing. Four hundred fifty ng of total RNA
from each of 57 cases was submitted to Illumina, Inc. (San Diego,
CA) for DASL-based labeling and hybridization to the Illumina
HumanRef8 v3 microarray. Using biotinylated random primers
and oligo-dT, 200 ng RNA was converted to cDNA. The
biotinylated cDNA was then immobilized to a streptavidin-
coated solid support and annealed by 24526 pairs of
oligonucleotides (18626 genes). Following extension and ligation,
the ligated oligonucleotides were PCR-amplified with biotinylated
or fluorophore-labeled universal primers and captured using
streptavidin paramagnetic beads. Finally, the products were
washed and denatured before hybridization to the BeadChips at
58uC for 16 hours. A BeadArray Reader extracted images and
read fluorescence intensities, and all data was uploaded into
BeadStudio software for quality control and processing.
Data preprocessing. Raw data exported from Illumina’s
BeadStudio underwent outlier removal, log2 transformation and
quantile normalization as implemented in the lumi package for R/
Bioconductor [75]. To simultaneously remove variance attributed
to batch and seizures, we performed batch and covariate
correction using ComBat [76]. Multivariate Distance Matrix
Regression [77] with 10,000 permutations confirmed that variance
attributable to batch and seizures were decreased following
correction. Detailed information regarding the methodology for
normalizing gene expression data and removing outliers is
provided in Chow et al. [78].
Statistical analysis
Filtering and differential expression analyses were performed
using BRBArrayTools (http://linus.nci.nih.gov/BRBArrayTools.
html). Filtering was performed based on variance and minimum
intensity. Probes with ,20% of expression values having at least a
1.5-fold up- or down-regulation from the gene’s median value
across cases, and probes with a minimum log intensity of less than
15 were excluded.
We identified 1086 probes with an interaction effect of age and
diagnosis by performing a two-way analysis of variance with 2
levels of diagnosis (autism and control) and 2 levels of categorical
age (2–14 years and 15–56 years, n=33). Interaction probes of
p,0.05, corresponding to an empirical FDR of 0.27 [79], were
selected for posthoc analysis to examine which differences were
driven by the young autism and young control groups and the
adult autism and adult control groups by t-tests (p,0.05) to
investigate gene expression changes in the young and adult autistic
brain. Probes exhibiting a main effect of diagnosis across age
groups were also identified (p,0.05, FDR=0.13).
Enrichment analysis
Enrichment analyses were performed using the MetaCore
software suite (www.genego.com/metacore.php) and DAVID
(http://david.abcc.ncifcrf.gov/) to examine the biological and
functional relevance of differentially expressed genes. These genes
were uploaded into MetaCore and filtered for known expression
specific to the brain or the fetal brain. The default background
gene list was used for all enrichment analyses. All results met
threshold of corrected p,0.05 and FDR,0.1 [80]. Gene
references used to confirm categorizations by MetaCore are listed
in Table S9.
Independent validation of microarray results
RNA from 1 male autistic and 1 control case both 31 years old
were analyzed using SYBR green RT-PCR to validate the
intensity values detected by microarray of 19 genes (Figure S2).
Primer3 software [81] was used to design primers across splice
junctions to produce amplicons of ,200 bp.
One mg of total RNA was used for cDNA synthesis using
random hexamers and AMV reverse transcriptase. An equivalent
of 50 ng of RNA was processed by qPCR using Roche’s
LightCycler rapid thermal cycler system (Roche Diagnostics Ltd,
Lewes, UK) according to the manufacturer’s instructions in a 96-
well, 10 mL format using standard PCR conditions. One mLo f
cDNA template, 250 nM of forward and reverse primer and 5 mL
of PCR Master Mix (Roche) were mixed for each reaction.
We took the geometric mean of all reference genes and the
difference between this mean and the average intensity of
experimental genes to find the delta Ct for each experimental
gene. Subsequently, log2 fold change was assessed using -(T-C)
where T=delta Ct of gene of the autistic case and C=delta Ct of
gene of the control case. Using Spearman’s rank correlation, the
log2 fold changes of these 19 genes across qPCR and microarray
platforms were found to be correlated at R=0.78 (p=0.000075,
DF=17; Figure S2).
Comparison between studies
Unique ProbeIDs of differentially expressed in the ‘initial’
dataset from Voineagu et al. [20] (file=‘nature10110-s3.xls’) were
compared with the differential expression gene list in the present
study comparing all autism and control cases. Genes overlapping
in each study with the present one were subjected to enrichment
analysis in MetaCore.
Copy Number Variation (CNV) detection and association
analysis
Fifty-five samples were genotyped on the Illumina 660 Bead
Array (Illumina Inc., San Diego, California) and SNP calls were
made using the Illumina Genome Studio software.
CNV calls were first obtained using the PennCNV software
(http://www.openbioinformatics.org/penncnv/) implementing
the wave adjustment procedure via the ‘‘–gcmodel’’ argument
[53] and then using the CNVision pipeline [54] to select for high
confidence CNV calls.
We first analyzed only male cases that passed QC (12 autism
and 12 controls; Figure 4) and identified a total of about 850
CNVs. Known nonpathogenic regions reported in the Database of
Genomic Variants (http://projects.tcag.ca/cgi-bin/variation/
gbrowse/hg18) were filtered without upper size limits. No large-
size CNVs (.1 Mb) were identified in single cases that could
potentially drive the gene enrichment results. We next analyzed
males and female cases together (14 autism and 16 controls; Figure
S4) using the same parameters and identified a total of about 1300
CNVs and then proceeded with the filtering of common regions.
We also excluded the possibility of a biased CNV detection given
the small sample size (Text S1 and Figure S4).
Due to possible high false positive rates, we re-analyzed all cases
using CNVision, a recently described analysis pipeline [54] (www.
cnvision.org) that merges results of PennCNV, QuantiSNP and
GNOSIS. The analysis of the male cases yielded about 350 CNVs
(11 autism and 13 controls). Gene enrichment was performed
considering both the gene content of gene-rich CNVs and the
nearest gene at the 5- and 3-prime end of gene-desert CNVs. As
performed with PennCNV alone, we next analyzed male and
female cases together but were unable to compare the gene
Autism Gene Expression and Copy Number Anomalies
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in the number of cases that passed QC (12 autism versus 19
controls).
GO enrichment of the gene content of these regions was also
performed using the MetaCore software suite (FDR,0.01 and
p,0.05). GeneGO Network Processes of each of these gene lists
are reported in Figure 4 and Figure S4.
Gene association analysis
For gene association analysis we utilized the AGRE-NIMH
Broad/Johns Hopkins Medical Institute (Broad/JHMI) sample as
our experimental dataset using original quality control filters and
the Children’s Hospital of Philadelphia (CHOP) sample dataset as
a replication sample, as previously described [56].
Gene sets were created using Gene Ontology (GO; http://
www.geneontology.org/), GeneGO (http://www.genego.com/
metacore.php) and the Wnt homepage (http://www.stanford.
edu/group/nusselab/cgi-bin/wnt/). We used PLINK [82]
(http://pngu.mgh.harvard.edu/,purcell/plink/) to retrieve the
SNPs within a window of 20 kb around each gene and to perform
set-based association analysis.
Significantly associated pathways (p,0.05) in the cell cycle gene
set were then broken down into 21 subsets of genes denoting
specific phases of the cell cycle using Ingenuity and set-based tests
were again performed on the experimental dataset. Subsets that
were found to be significant in the Broad/JHMI sample were then
tested on the CHOP sample for replication using the same set-
based analysis.
Supporting Information
Figure S1 Venn diagram showing differentially expressed genes
in young autism vs. young control, adult autism vs. adult control
and diagnosis main effect ANOVA analyses.
(TIF)
Figure S2 Log2foldchangecorrelationsofselectedgenesdetected
by microarray and RT-PCR, and primer sequences. (A) Log2 Fold
change detected by RT-PCR is depicted on the x-axis, and change
detected by microarray is on the y-axis. Spearman’s rank correlation
detected R=0.78 (p=0.000075, DF=17) correlation between
microarray and qPCR detection of fold change. (B) Forward and
reverse primer sequences for 19 experimental and 3 reference genes
used for RT-PCR to validate gene expression microarray results.
(TIF)
Figure S3 Third most significant map folder of diagnosis main
effect analysis. Graph on left shows fold change of genes in
Immune Response Map Folder. This map folder was third most
significant in the comparison between all autistic and all control
cases. From each category of differentially expressed genes in the
all autistic vs. all control comparison (Table S5), networks were
created using MetaCore Network Analysis. Genes with blue circles
were differentially expressed; genes without circles were sum-
moned by the database to complete network.
(TIF)
Figure S4 Enrichment of CNVs detected in the DLPFC of male
and female samples. Metacore analysis of GeneGO Processes
significantly represented in genes contained within: (A) total CNVs
and B) filtered (i.e., not present in the Database of Genomic
Variants) CNVs. Blue bars, controls. Red bars, autistic cases. C)
Average number of CNVs in autistic cases and controls. D)
Average number of genes per CNV in autistic and control cases. E)
Average CNV size comparison between autistic cases and controls.
C–E) No statistically significant differences were found between
autistic cases and controls, suggesting non-biased CNV detection
potentially due to the small sample size. F) Size distribution of the
filtered CNVs in the autistic cases is shown.
(TIF)
Table S1 Demographics and clinical information of postmortem
cases. (A) ID, diagnosis, age, gender, study, DLPFC RNA integrity
number (RIN), basis of diagnosis, ADI measures, and intellectual
disability for cases in present study are documented. RIN #1w a s
performed at the UCSD Biogem core, RIN #2 was performed at
UCSFintheWynshaw-Boris lab,and RIN#3 wasperformed at the
Allen Institute. ADI-R=Autism Diagnostic Interview-Revised;
ADOS=Autism Diagnostic Observation Schedule; CNV=copy
number variation; ISH=in situ hybridization; Comm=Communi-
cation; R & R=Restricted and Repetitive behavior; DLPFC=Dor-
solateral Prefrontal Cortex; RIN=RNA integrity number;
M=male; F=female; v=verbal; nv=nonverbal; Y=yes; N=no;
TARF=existing diagnostic status on donation from The Autism
Research Foundation, no other records available; ATP=existing
diagnostic status on case from the Autism Tissue Program, no
documents available at this date. Pink X=case passed quality
control measures for gene expression/CNV analysis; black X=case
was processed but did not pass quality control measures for CNV
analysis. (B). Detailed clinical information of autistic cases. Available
clinical information, including information from the ADI-R
assessment, noted seizure activity and intellectual disability, is
provided for autistic cases in this study. Assessments were made by
a clinical psychologist (C.C.B.). ADI=Autism Diagnostic Interview;
RIN=RNA Integrity Score; HX=History; DO=Diagnosis; ADI
Comm Score=ADI-R Communication Score; ADI R&R Scor-
e=ADI-RRestrictedandRepetitiveBehaviorScore;IVF=InVitro
Fertilization. (C) Detailed clinical information of autistic and control
cases. Available clinical information is provided for autistic and
control cases in this study. Assessments were made by a clinical
psychologist (C.C.B.). HX=History; DO=Diagnosis; IVF=In
Vitro Fertilization; PMI=Postmortem Interval.
(PDF)
Table S2 Differentially expressed genes in young autistic cases.
All 102 differentially expressed genes in the posthoc comparison
passing a threshold of p,0.05 between young autism and young
control cases of genes showing an effect of interaction between
diagnosis and categorical age. Gene symbols, Illumina probe IDs,
p-Value of difference, cytogenetic bands and fold changes are
listed. Bold genes are shown in Figure 1.
(PDF)
Table S3 Dysregulatedgenesofyoungautisticcasesandpreviously
identified candidate genes and loci. Loci of 102 differentially
expressed genes in the posthoc comparison and references of previous
linkage/association/CNVstudiesimplicatingthecandidatelocusand
references of other genes neighboring the candidate loci are listed.
NEGATIVE=negative association/linkage.
(PDF)
Table S4 Top downregulated and upregulated genes in adult
autistic cases. Genes showing greatest fold change difference in the
posthoc comparison passing a threshold of p,0.05 between adult
autism and adult control cases of genes showing an effect of
interaction between diagnosis and categorical age. Gene symbols,
Illumina probe IDs, p-Value of difference, cytogenetic bands and
fold changes are listed.
(PDF)
Table S5 Top downregulated and upregulated genes of male
autistic cases across all young and older ages (2 to 56 years). Genes
showing greatest fold change differences and a main effect of
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control cases, Illumina probe IDs, p-value of difference, cytoge-
netic bands and fold changes are listed.
(PDF)
Table S6 Significant dysregulated pathways of autistic cases
across all young and older ages (2 to 56 years). Dysregulated
pathways enriched in genes showing a main effect of diagnosis
(p,0.05; FDR,0.1) identified using the MetaCore software suite
between autism and control cases, p-value and network objects are
listed. Pathways are sorted by pathway category name.
(PDF)
Table S7 Chromosomal locations of CNV regions found in all
autistic cases (males and females). Chromosomal location, number
(N) of SNPs, size of the SNP in base pairs (bp) and annotated gene
content of CNV regions found in all autistic cases (males and
females) are listed. Overlapping regions with the same gene
content but different breakpoints are listed as distinct CNVs.
Enrichment results are presented in Figure 4.
(PDF)
Table S8 Chromosomal locations of CNV regions found in all
control cases (males and females). Chromosomal location, number
(N) of SNPs, size of the SNP in base pairs (bp) and annotated gene
content of CNV regions found in all control cases (males and
females) are listed. Overlapping regions with the same gene
content but different breakpoints are listed as distinct CNVs.
Enrichment results are presented in Figure 4.
(PDF)
Table S9 References for genes in noted pathways and networks.
Important genes from the pathways and networks identified by
gene expression analyses are listed. Gene category, references, and
analysis corresponding to these genes are presented. Gex=gene
expression.
(PDF)
Text S1 Supporting materials. Supplementary methods, ac-
knowledgements and figures are provided.
(DOCX)
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